Aclaris Shares Fall 7.7% as Investors Weigh $50 Million Offering
Aclaris Therapeutics shares fell about 7.7% in premarket trading as investors weighed a discounted $50 million share offering, despite positive early-stage trial results for its experimental asthma and eczema treatment.